4 Stocks Pushing The Health Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 84 points (-0.5%) at 15,367 as of Wednesday, Aug. 14, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,073 issues advancing vs. 1,847 declining with 114 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Mindray Medical International ( MR), down 2.0%, Agilent Technologies ( A), down 0.9% and Aetna ( AET), down 0.7%. Top gainers within the industry include Alere ( ALR), up 2.6%, Medtronic ( MDT), up 0.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Parexel International Corporation ( PRXL) is one of the companies pushing the Health Services industry lower today. As of noon trading, Parexel International Corporation is down $1.91 (-3.7%) to $49.42 on heavy volume. Thus far, 397,197 shares of Parexel International Corporation exchanged hands as compared to its average daily volume of 512,300 shares. The stock has ranged in price between $48.58-$50.00 after having opened the day at $49.79 as compared to the previous trading day's close of $51.33.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. Parexel International Corporation has a market cap of $2.9 billion and is part of the health care sector. Shares are up 72.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Parexel International Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Parexel International Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Zimmer Holdings ( ZMH) is down $0.63 (-0.8%) to $81.22 on light volume. Thus far, 272,455 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 976,600 shares. The stock has ranged in price between $81.03-$82.12 after having opened the day at $81.91 as compared to the previous trading day's close of $81.85.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $14.0 billion and is part of the health care sector. Shares are up 23.5% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Zimmer Holdings a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Zimmer Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Catamaran ( CTRX) is down $0.50 (-0.9%) to $57.04 on light volume. Thus far, 245,158 shares of Catamaran exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $56.84-$57.53 after having opened the day at $57.39 as compared to the previous trading day's close of $57.54.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $11.8 billion and is part of the health care sector. Shares are up 21.5% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Cigna ( CI) is down $0.59 (-0.8%) to $78.38 on light volume. Thus far, 479,260 shares of Cigna exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $78.12-$78.90 after having opened the day at $78.75 as compared to the previous trading day's close of $78.97.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $22.2 billion and is part of the health care sector. Shares are up 46.8% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cigna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs